New Delhi / In a landmark development for public health and infectious disease prevention, India has approved QDENGA (TAK-003), the first dengue vaccine to receive approval in the country. Developed by Takeda, the vaccine is designed to provide protection against all four dengue virus serotypes—DENV-1, DENV-2, DENV-3, and DENV-4—offering a significant new tool in the fight against one of India’s most widespread mosquito-borne diseases.
According to Dr. Aishwarya R, Consultant – Infectious Diseases, Aster RV Hospital, Bengaluru, the approval represents a major advancement in India’s efforts to reduce the burden of dengue fever, which affects millions of people every year and places considerable pressure on the country’s healthcare system during seasonal outbreaks.
Vaccine Coverage and Administration
The newly approved QDENGA (TAK-003) is indicated for individuals aged 4 to 60 years and is administered as a two-dose vaccination schedule, with the second dose given three months after the first.
One of the vaccine’s key advantages is that no pre-vaccination blood test is required before receiving the vaccine, making it easier to integrate into routine immunization programs.
As a live attenuated vaccine, QDENGA works by stimulating the body’s immune system to produce protective antibodies and immune cells capable of recognizing and responding rapidly to the dengue virus if exposure occurs in the future.
Protection Against All Four Dengue Serotypes
Health experts emphasize that infection with one dengue virus serotype does not provide immunity against the remaining three. In fact, a second infection caused by a different serotype can increase the risk of developing severe dengue, including dengue hemorrhagic fever and dengue shock syndrome.
By providing protection against all four serotypes, QDENGA aims to reduce the likelihood of severe disease, minimize complications, and lower hospitalization rates.
Clinical Benefits
Clinical studies have demonstrated encouraging results for QDENGA, including:
- 80% reduction in symptomatic dengue cases during the first year after vaccination.
- 90% reduction in dengue-related hospitalizations.
- Protective efficacy lasting up to 4.5 years following vaccination.
These findings suggest that widespread vaccination could significantly reduce the burden on hospitals, intensive care units (ICUs), and healthcare resources during dengue outbreaks.
Who Should Avoid the Vaccine?
Because QDENGA is a live vaccine, it is not recommended for:
- Pregnant women.
- Individuals receiving immunosuppressive medications.
- Certain people with significantly weakened immune systems, based on medical advice.
Healthcare providers recommend consulting a qualified physician before vaccination, particularly for individuals with underlying medical conditions.
Vaccination Does Not Replace Mosquito Control
Medical experts stress that vaccination should complement—not replace—existing dengue prevention measures.
People are advised to continue:
- Eliminating mosquito breeding sites.
- Using mosquito repellents.
- Wearing protective clothing.
- Installing window screens or using mosquito nets where appropriate.
- Seeking immediate medical attention for symptoms such as persistent high fever, severe headache, vomiting, abdominal pain, or bleeding.
Combining vaccination with effective mosquito control remains the most comprehensive strategy for reducing dengue transmission.
International Perspective
Commenting on India’s approval of the vaccine, Dr. Michael Harris, an American infectious disease specialist, said:
“The approval of a vaccine that targets all four dengue virus serotypes is a significant milestone. It has the potential to reduce severe illness, hospitalizations, and the overall public health burden in dengue-endemic countries.“
Meanwhile, Dr. Jennifer Collins, a U.S.-based vaccine research expert, observed:
“Vaccination, combined with mosquito control and public awareness, offers the strongest defense against dengue. India’s decision to approve QDENGA represents an important advancement in preventive healthcare.“
Key Highlights
- India has approved QDENGA (TAK-003), developed by Takeda, as the country’s first approved dengue vaccine.
- The vaccine protects against all four dengue virus serotypes—DENV-1, DENV-2, DENV-3, and DENV-4.
- It is approved for individuals aged 4 to 60 years.
- The vaccination schedule consists of two doses, administered three months apart.
- No pre-vaccination blood test is required.
- Clinical studies reported an 80% reduction in symptomatic dengue and a 90% reduction in dengue-related hospitalizations, with protection lasting up to 4.5 years.
- As a live attenuated vaccine, it is not recommended for pregnant women or individuals receiving immunosuppressive therapy.
- Health experts emphasize that vaccination should be combined with mosquito control measures, personal protection, and early medical care to effectively reduce the impact of dengue.
